RecruitingNCT06611020

Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia

The Role of Adjuvant VaccInation After Conization for the Treatment for Cervical Dysplasia

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Enrollment

600 participants

Start Date

Jan 1, 2020

Study Type

OBSERVATIONAL

Conditions

Cervical Intraepithelial Neoplasia

Summary

HPV vaccination has emerged as a strategy to reduce the risk of recurrence oafter excisional treatment. However, only few data are aviable. In this trial the investigators aim to assess the role of HPV vaccination in women traeted for HPV-related lesions

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether receiving an HPV vaccine after a cervical procedure called conization (removal of abnormal tissue caused by HPV) can prevent the dysplasia (precancerous cells) from coming back. Conization treats the problem but doesn't eliminate the HPV virus, so vaccination may help the immune system clear it. **You may be eligible if...** - You have had or are having a conization procedure for HPV-related cervical abnormalities **You may NOT be eligible if...** - You have already received an HPV vaccine in the past Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.